The cell and gene therapy contract development and manufacturing organization (CDMO) market is poised for significant growth, reaching an estimated USD 29.49 billion by 2035. This surge is propelled by an increasing number of advanced therapies being developed worldwide, particularly in oncology, rare diseases, and genetic disorders.
Market Growth Projections
The U.S. cell and gene therapy CDMO market is expected to see a remarkable rise from USD 2.09 billion in 2025 to USD 10.28 billion by 2035, reflecting a compound annual growth rate (CAGR) of 17.26%. This growth can be attributed to a robust pipeline of cell and gene therapy initiatives, strong regulatory support from bodies like the FDA, and an escalating trend of outsourcing among biopharma companies.
Factors Driving Market Expansion
The rapid growth of the cell and gene therapy CDMO market is fueled by several key factors. Biopharma companies are increasingly recognizing the need for specialized CDMO services to navigate the complexities of advanced therapies. This includes the high costs associated with manufacturing and the stringent regulatory landscape, which compel firms to partner with CDMOs for both development and production.
Moreover, regulatory incentives, such as the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation, facilitate faster clinical translation and commercialization of these therapies. These elements collectively enhance the attractiveness of outsourcing, allowing companies to focus on their core competencies while leveraging the expertise of CDMOs.
Segmentation Insights
In 2025, cell therapy is anticipated to dominate the market, holding a 49% share, driven largely by the proliferation of clinical-stage and commercial programs, including CAR-T and stem-cell-based therapies. Conversely, gene therapy is identified as the fastest-growing modality, supported by an expanding pipeline for adeno-associated virus (AAV) and lentiviral products aimed at treating rare genetic and neurological disorders.
Manufacturing services will account for 57% of the market share due to their capital-intensive nature and the complexity of processes involved. The process and analytical development segment is expected to grow rapidly, reflecting the increasing demand for scalable and reproducible processes in the early-stage cell and gene therapy pipeline.
Regional Market Dynamics
North America leads the global cell and gene therapy CDMO market, contributing approximately 45% of total revenue. This dominance is attributed to a dense concentration of biotech and pharmaceutical firms, a vast clinical development pipeline, and robust regulatory frameworks.
In contrast, the Asia-Pacific region is projected to be the fastest-growing market, with a CAGR of 23.05% from 2026 to 2035. This growth is driven by an increase in biomanufacturing capacity, cost-effective production solutions, and supportive government policies aimed at advancing therapeutic innovations.
Key Players and Industry Developments
Several organizations are at the forefront of this dynamic market. For instance, Lonza has expanded its cell and gene therapy manufacturing capacity in the United States to meet the rising demand for late-stage and commercial programs. Similarly, Catalent has enhanced its viral vector manufacturing capabilities through strategic investments in technology and facility upgrades.
Market Takeaways
- The cell and gene therapy CDMO market is projected to grow to USD 29.49 billion by 2035.
- The U.S. sector is set to expand significantly, driven by strong regulatory support and an increasing number of therapies.
-
Cell therapy dominates the market, while gene therapy is the fastest-growing segment.
-
North America leads in market share, with Asia-Pacific exhibiting the highest growth potential.
-
Biopharmaceutical companies are the primary end-users, but startups are emerging as a rapidly growing segment.
Conclusion
The future of the cell and gene therapy CDMO market is bright, driven by technological advancements and an expanding pipeline of therapies. As biopharma companies increasingly seek specialized services to navigate the complexities of development and production, CDMOs will play an essential role in the successful commercialization of innovative therapies. The industry’s growth trajectory promises not only to enhance patient outcomes but also to reshape the landscape of modern medicine.
Read more → finance.yahoo.com